TPST Stock Overview
Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Tempest Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.69 |
| 52 Week High | US$9.77 |
| 52 Week Low | US$0.17 |
| Beta | -2.83 |
| 1 Month Change | -0.81% |
| 3 Month Change | -7.40% |
| 1 Year Change | 80.00% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -72.38% |
Recent News & Updates
Shareholder Returns
| TPST | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 4.2% | 4.8% | 0.7% |
| 1Y | 80.0% | 2.8% | 23.9% |
Return vs Industry: TPST exceeded the US Biotechs industry which returned 2.8% over the past year.
Return vs Market: TPST exceeded the US Market which returned 23.9% over the past year.
Price Volatility
| TPST volatility | |
|---|---|
| TPST Average Weekly Movement | 16.1% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: TPST's share price has been volatile over the past 3 months.
Volatility Over Time: TPST's weekly volatility has decreased from 563% to 16% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 17 | Steve Brady | www.tempesttx.com |
Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company’s two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition.
Tempest Therapeutics, Inc. Fundamentals Summary
| TPST fundamental statistics | |
|---|---|
| Market cap | US$81.98m |
| Earnings (TTM) | -US$29.49m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.8x
P/E RatioIs TPST overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TPST income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$29.49m |
| Earnings | -US$29.49m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.33 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 39.4% |
How did TPST perform over the long term?
See historical performance and comparison